

Amendment

The following listing of claims will replace all prior versions and listings of claims in the application.


Listing of the Claims:

1-12. (Cancelled)

13. (Currently Amended) A vaccine for preventing viral-infections with influenza virus comprising:

an influenza virus antigen;

a peptide (Peptide A) comprising a sequence R₁-XZX_NXZX-R₂, whereby N is a whole number between 3 and 7, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R₁ and R₂ are independently -H, -NH₂, -COCH₃, -COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X-R₂ is an amide, ester or thioester of the C-terminal amino acid residue of the peptide; and an immunostimulatory oligodeoxynucleic acid molecule (I-/U-ODN) having the structure according to the formula (I):



wherein:

R1 is selected from hypoxanthine and uracile;
any X is O or S;
any NMP is a 2' deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate;
NUC is a 2' deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyinosine-, deoxythymidine-, 2-methyl-deoxyuridine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine;
a and b are integers from 0 to 100 with the proviso that a + b is between 4 and 150; and
B and E are common groups for 5' or 3' ends of nucleic acid molecules.

14. (Previously Presented) The vaccine of claim 13, wherein N is 5.
15. (Previously Presented) The vaccine of claim 13, further comprising an $\text{Al}(\text{OH})_3$ adjuvant.
- 16-17. (Canceled)
18. (Currently Amended) The vaccine of claim [[18]]13, wherein the ~~viral antigen~~ is an influenza antigen further defined as is a haemagglutinin antigen or a neuraminidase antigen.
19. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide.
20. (Currently Amended) The vaccine of claim 13, wherein Peptide A is KLKL₅KLK (SEQ ID NO:6) and the I/U-ODN is oligo d(IC)₁₃.

21. (Previously Presented) The vaccine of claim 13, further comprising an oligodeoxynucleotide containing a CpG-motif.
22. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide and an oligodeoxynucleotide containing a CpG-motif.
- 23.-28. (Canceled)